HUP0301773A2 - Apomorfinszármazékok és alkalmazásaik - Google Patents

Apomorfinszármazékok és alkalmazásaik

Info

Publication number
HUP0301773A2
HUP0301773A2 HU0301773A HUP0301773A HUP0301773A2 HU P0301773 A2 HUP0301773 A2 HU P0301773A2 HU 0301773 A HU0301773 A HU 0301773A HU P0301773 A HUP0301773 A HU P0301773A HU P0301773 A2 HUP0301773 A2 HU P0301773A2
Authority
HU
Hungary
Prior art keywords
apomorphine
methods
compounds
po3h2
so3h
Prior art date
Application number
HU0301773A
Other languages
English (en)
Inventor
Pramod K. Gupta
Deborah Milkowski
Debra Sutkowski-Markham
Original Assignee
Tap Pharmaceutical Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Products Inc. filed Critical Tap Pharmaceutical Products Inc.
Publication of HUP0301773A2 publication Critical patent/HUP0301773A2/hu
Publication of HUP0301773A3 publication Critical patent/HUP0301773A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

A találmány tárgyát apomorfinszármazék-vegyületek képezik, melyekszerkezete a következő képlettel jellemezhető: ahol n jelentése 1 és 4közötti egész szám, R1 jelentése: hidrogén-, alkil-, -PO3H2, -SO3Hvagy glükuronilcsoport, R2 jelentései egymástól függetlenülválaszthatóan hidrogén-, alkil-, -PO3H2, -SO3H vagy glükuronilcsoport; vagy a vegyületek gyógyászati szempontból elfogadható sója.Valamint a találmány további tárgyát a vegyületek nemi működészavarkezelésére szolgáló eljárásokban, valamint apomorfinos kezeléshatékonyságának fokozására történő alkalmazásai képezik. Előnyös atalálmány szerinti apomorfinszármazékok a norapomorfin. Ó
HU0301773A 2000-04-07 2001-03-29 Apomorphine derivatives and methods for their use HUP0301773A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19565000P 2000-04-07 2000-04-07
PCT/US2001/040393 WO2001076602A1 (en) 2000-04-07 2001-03-29 Apomorphine derivatives and methods for their use

Publications (2)

Publication Number Publication Date
HUP0301773A2 true HUP0301773A2 (hu) 2003-09-29
HUP0301773A3 HUP0301773A3 (en) 2006-02-28

Family

ID=22722192

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301773A HUP0301773A3 (en) 2000-04-07 2001-03-29 Apomorphine derivatives and methods for their use

Country Status (18)

Country Link
US (1) US6506765B2 (hu)
EP (1) EP1284735A4 (hu)
JP (1) JP2003532640A (hu)
KR (1) KR20030036157A (hu)
CN (1) CN1471395A (hu)
AU (1) AU2001255818A1 (hu)
BG (1) BG107217A (hu)
BR (1) BR0109515A (hu)
CA (1) CA2405419A1 (hu)
CZ (1) CZ20023637A3 (hu)
HU (1) HUP0301773A3 (hu)
IL (1) IL151614A0 (hu)
MX (1) MXPA02009904A (hu)
NO (1) NO20024806D0 (hu)
PL (1) PL361672A1 (hu)
SK (1) SK15772002A3 (hu)
WO (1) WO2001076602A1 (hu)
ZA (1) ZA200207489B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
BR0308567A (pt) * 2002-03-19 2007-01-09 Michael Holick derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos
WO2004069167A2 (en) * 2003-01-31 2004-08-19 Nastech Pharmaceutical Company Inc. Method and compositions for treating male infertility
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
EP1613323A1 (en) * 2003-04-14 2006-01-11 Vectura Limited Pharmaceutical compositions comprising apomorhine for pulmonary inhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
ZA200803087B (en) 2005-10-12 2009-11-25 Unimed Pharmaceuticals Llc Improved testosterone gel and method of use
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
TWI816716B (zh) 2017-11-24 2023-10-01 丹麥商Ｈ 朗德貝克公司 用於治療帕金森病之新兒茶酚胺前驅藥
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
AU6428894A (en) 1993-03-26 1994-10-24 Franciscus W.H.M. Merkus Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine
EP0978282B1 (en) 1994-04-22 2005-12-14 Pentech Pharmaceuticals, Inc. Sublingual composition containing apomorphine for diagnosing functional impotence
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
PT914097E (pt) 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US5925629A (en) * 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
AU751182B2 (en) 1997-12-02 2002-08-08 Archimedes Development Limited Compositions for nasal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
CA2334550A1 (en) * 1998-06-22 1999-12-29 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
IT1299566B1 (it) * 1998-07-17 2000-03-16 Ifi Istituto Farmacoterapico I Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
MXPA01011480A (es) * 1999-05-13 2002-06-04 Unihart Corp Composiciones farmaceuticas que comprenden apocodeina y/o sus derivados.

Also Published As

Publication number Publication date
BG107217A (bg) 2003-05-30
AU2001255818A1 (en) 2001-10-23
EP1284735A4 (en) 2006-01-11
NO20024806D0 (no) 2002-10-04
KR20030036157A (ko) 2003-05-09
HUP0301773A3 (en) 2006-02-28
US6506765B2 (en) 2003-01-14
CA2405419A1 (en) 2001-10-18
SK15772002A3 (sk) 2003-09-11
CZ20023637A3 (cs) 2003-02-12
MXPA02009904A (es) 2004-09-06
PL361672A1 (en) 2004-10-04
ZA200207489B (en) 2003-12-18
JP2003532640A (ja) 2003-11-05
BR0109515A (pt) 2004-08-10
WO2001076602A1 (en) 2001-10-18
IL151614A0 (en) 2003-04-10
EP1284735A1 (en) 2003-02-26
US20020002176A1 (en) 2002-01-03
CN1471395A (zh) 2004-01-28

Similar Documents

Publication Publication Date Title
HUP0301773A2 (hu) Apomorfinszármazékok és alkalmazásaik
ATE437872T1 (de) Proteinkinaseinhibitoren
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
CY1105579T1 (el) Kαρβαμιδο - υποκατεστημενες πυραζολοπυριδινες
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
CY1109558T1 (el) Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων
CY1108808T1 (el) Ενωσεις μοτιλιδης
MXPA04004370A (es) Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
HUP9802678A2 (hu) Biciklusos aminszármazékok és ezeket tartalmazó PGD2 antagonista hatású készítmények
MXPA06001494A (es) Compuestos de piramidina condensados como inhibidores de canales ionicos gatillados por tension.
SG151260A1 (en) 5-substituted-2-phenylamino-benzamides as mek inhibitors
GB0413087D0 (en) Therapeutic compounds
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
NO20033959L (no) Benzimidazoler som er nyttige i behandling av seksuell dysfunksjon
ATE272617T1 (de) Sulfonamid-derivate
UA83821C2 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
BRPI0418375A (pt) derivados de diaza-espiropiperidina
PE20040975A1 (es) Derivados de aril- y heteroarilmorfolina
DE60227113D1 (de) Kondensierte camptothecine als antitumormittel
UY26111A1 (es) Derivados de ciclobuten-3, 4-diona, su preparación y su aplicación en terapéutica
MXPA04000615A (es) Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor.
TH76785B (th) สารประกอบลาพาโคนชนิดใหม่และวิธีใช้มัน

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished